> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Clears Profound Medical Ablation Module
- URL: https://www.fdaweb.com/fda-clears-profound-medical-ablation-module/
- Published: 2023-09-25T12:00:00.000Z
- Updated: 2026-09-14T18:58:06.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5155406

FDA has cleared a Profound Medical 510(k) for the company’s Thermal Boost module for use in conjunction with its Tulsa-Pro, which permits surgeons to ablate whole- or partial-gland prostate tissue in patients with low-, intermediate-, or high-risk prostate cancer; with benign prostatic hyperplasia (BPH); as well as those prostate cancer patients on active surveillance seeking treatment of their cancer and relief from BPH symptoms.

The Thermal Boost module enables surgeons to temporarily increase the ablation target temperature in prostate regions where advanced-stage cancer might be located, further increasing their confidence that aggressive cancer cells have been ablated, Profound Medical says. “Achieving complete thermal coverage is critical to successful prostate disease treatment, so being able to customize ablation temperature in real time has improved treatment efficacy as well as workflow efficiency,” it adds.